Red Tree Venture β Full Portfolio
22 tracked investments Β· listed companies and verified rows first
BiotechSouth San Francisco, US
Grant E Pickering(Executive Officer, Director, Promoter)Ashish Khanna(Executive Officer)Jeff Fairman(Executive Officer)
BoardTracy Saxton(Director)William Newell(Director)Kurt von Emster(Director)in
Board seatHeath LukatchΒ· per SEC Form D Β· $110M raise Β· filed Apr 2020
Co-investorsAbingworthFrazier Life SciencesMedicxiPivotal Life Sciences
Co-investorsAisling CapitalEight Roads VenturesF-Prime CapitalForesite CapitalPremji InvestRA Capital+1 more
Ceribell is a medical technology company that develops products for detecting and monitoring seizures, including EEG-based diagnostic systems.
AI & Machine LearningDigital HealthHealthtechMedical DevicesSunnyvale, US
Josef Parvizi(Director)Xingjuan Chao(Executive Officer, Director)Xingjuan (Jane) Chao(President, CEO, Co-Founder & Director)Scott Blumberg(Executive Officer)Joseph Taylor(Director)Raymond Woo(Executive Officer)
Co-investorsLongitude CapitalRA CapitalShangBay Capital LLC
Contineum Therapeutics develops therapies targeting conditions at the intersection of inflammatory and fibrotic diseases, including a candidate for idiopathic pulmonary fibrosis (IPF) and chronic pain, and a candidate for major depressive disorder (MDD) developed with Janssen Pharmaceutica.
BiotechHealthtech
Co-investorsHadean VenturesSamsara BioCapital
BiotechSan Francisco, US
Donald Manning(Executive Officer)Scott Harris(Executive Officer)Julien Mamet(Executive Officer, Director)Rick Orr(Executive Officer, Director)
BoardDennis Podlesak(Director)Eckard Weber(Director)
Board seatHeath LukatchΒ· per SEC Form D Β· $16M raise Β· filed Jan 2017
Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)Anup Radhakrishnan(Executive Officer)Cassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)
BoardAbraham Bassan(Director)
Board seatHeath LukatchΒ· per SEC Form D
Co-investorsNextech InvestSamsara BioCapitalAlly Bridge GroupJanus Henderson InvestorsPerceptive Xontogeny VentureThird Rock Ventures
BiotechBedford, US
Arthur Klausner(Executive Officer, Director)
BoardScott Minick(Director)
Board seatKrishna PoluΒ· per SEC Form D Β· $1.2M raise Β· filed Apr 2021
Acquired.
Digital HealthHardwareWellness & FitnessSan Francisco, US
Daniel Chao, M.D., M.S.(Executive Officer, Director)Daniel Chao(Executive Officer, Director)
BoardAndrew Firlik(Director)inPeter Hebert(Director)inAmol Sarva(Director)
Board seatHeath LukatchΒ· per SEC Form D Β· $19.8M raise Β· filed May 2018
Co-investorsJAZZ Venture PartnersLux Capital
Magnus Medical develops SAINT, an FDA-cleared, accelerated form of TMS (transcranial magnetic stimulation) therapy that uses precision neuromodulation to treat Major Depressive Disorder, including treatment-resistant depression, over a 5-day course.
BiotechDigital HealthMedical DevicesMental HealthBurlingame, US
Nolan Williams(Director)Christian Gormsen(Executive Officer, Director)Vikram Lamba(Executive Officer)
BoardXingjuan Chao(Director)Andrew Firlik(Director)in
Board seatHeath LukatchΒ· per SEC Form D Β· $77M raise Β· filed May 2026
Co-investorsJAZZ Venture PartnersDolby Family Ventures
Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101).
BiotechHealthtechMedical DevicesSouth San Francisco, US
John Kollins(Executive Officer, Director)Tadayoshi Iwashima(Executive Officer)Thomas B. King(President and Board Director)Rob Janosky(Chief Commercial Officer)Tom O'Neil(Chief Financial Officer)David Prichard(Chief Operating Officer)
Board seatHeath LukatchΒ· per SEC Form D Β· $12.3M raise Β· filed Feb 2018
Co-investorsOUP (Osage University Partners)Vivo Capital
BiotechSan Diego, US
Brittany Bradrick(Executive Officer)Anne Sandan(Executive Officer)Elizabeth Bui(Executive Officer)Steve White(Executive Officer)Howard Foyt(Executive Officer)Donald J. Elmer(Director)
Board seatHeath LukatchΒ· per SEC Form D Β· $90M raise Β· filed Dec 2018
Co-investorsBain Capital Life SciencesRA CapitalSanderling VenturesThe Vertical Group
BiotechSan Francisco, US
Leah Makley(Executive Officer, Director)Ed Hurwitz(Executive Officer, Director)Jason E. Gestwicki(Director)
BoardDouglas Crawford(Director)Emmett T. Cunningham, Jr.(Director)Mark Blumenkranz, M.D.(Director)
Board seatHeath LukatchΒ· per SEC Form D Β· $35M raise Β· filed Mar 2018
Developing therapies for autoimmune disease.
Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.
BiotechDigital HealthMedical DevicesSan Diego, US
Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)Vikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)
Co-investorsForesite CapitalLongwood FundNorwest Venture PartnersRiverVest Venture PartnersYsios Capitalabrdn plc+4 more
Life science company that raised a $70M Series A; Red Tree backed from the seed round.
Developing best-in-class protein therapeutics for rapidly relieving or preventing allergic-mediated diseases.
Co-investorsSamsara BioCapital
Kivu Bioscience is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology, using site-specific conjugation technology to create more stable and homogeneous cancer therapies with reduced off-tumor toxicity.
BiotechDeep TechHealthtech
Mohit Trikha(CEO)
Co-investorsBOMHealthCapM VenturesBioGeneration VenturesNovo Holdings
Drug development company whose Series A was led by Red Tree.
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.